Data updated: Mar 29, 2026
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
EMTRICITABINE
Approved 2024-05-17
2
Indications
--
Phase 3 Trials
1
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2024-05-17
- Routes
- ORAL
- Dosage Forms
- TABLET
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Approval History
Loading approval history...
What EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Treats
2 FDA approvalsOriginally approved for its first indication in 2024 . Covers 2 distinct patient populations.
- Other (2)
Other
(2 approvals)- • Approved indication (May 2024)Letter
- • Approved indication (Dec 2024)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.